Pancreatic Cancer Research

ResearcherUniversity of Colorado Cancer CenterActive in the last 2 years

Christopher Hanyoung Lieu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4852-4642; OpenAlex author ID A5012289008. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection. Co-author DOI 10.1021/acsnano.5c10607↗
  2. Oligometastatic pancreatic cancer: current state of management and emerging therapies. Co-author DOI 10.1093/oncolo/oyaf154↗
  3. Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). Co-author DOI 10.1371/journal.pone.0298808↗
  4. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.05.008↗
  5. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Co-author DOI 10.1158/2767-9764.crc-23-0065↗
  6. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
  7. Neoadjuvant treatment of localized pancreatic adenocarcinoma. Last author DOI 10.21037/jgo-20-250↗
  8. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.642328↗
  9. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Co-author DOI 10.1097/mpa.0000000000000876↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wells A. Messersmith · 8 shared papers, 2017–2025 · strength 1.28
  2. Alexis Diane Leal · 5 shared papers, 2021–2024 · strength 0.76
  3. Todd M. Pitts · 4 shared papers, 2021–2025 · strength 0.69
  4. Robert William Lentz · 3 shared papers, 2023–2025 · strength 0.61
  5. Marco Del Chiaro · 3 shared papers, 2021–2025 · strength 0.55
  6. Sarah J. Hartman · 2 shared papers, 2021–2024 · strength 0.29
  7. Andrii Khomiak · 1 shared paper, 2025 · strength 0.28
  8. Sarah Lindsey Davis · 3 shared papers, 2017–2021 · strength 0.28
  9. Ana Gleisner · 2 shared papers, 2021–2023 · strength 0.26
  10. Richard David Schulick · 2 shared papers, 2021–2023 · strength 0.26
  11. Sana D. Karam · 2 shared papers, 2021–2023 · strength 0.25
  12. Komila Rasuleva · 1 shared paper, 2025 · strength 0.25
  13. Alfred Akinlalu · 1 shared paper, 2025 · strength 0.25
  14. Pankaj Kumar Singh · 1 shared paper, 2025 · strength 0.25
  15. Haiyong Han · 1 shared paper, 2025 · strength 0.25
  16. Dali Sun · 1 shared paper, 2025 · strength 0.25
  17. John J. Arcaroli · 1 shared paper, 2024 · strength 0.18
  18. Hayley J Hawkins · 1 shared paper, 2024 · strength 0.18
  19. Toshitaka Sugawara · 1 shared paper, 2023 · strength 0.17
  20. Christina M. Stuart · 1 shared paper, 2023 · strength 0.17
  21. Robert Alexander Meguid · 1 shared paper, 2023 · strength 0.17
  22. Karyn A. Goodman · 2 shared papers, 2017–2021 · strength 0.16
  23. Stephen Leong · 2 shared papers, 2017–2021 · strength 0.16
  24. Carlo Marchetti · 1 shared paper, 2023 · strength 0.15
  25. Jesús Amo‐Aparicio · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.